Skip to main content
. 2015 Jul 2;6:7353. doi: 10.1038/ncomms8353

Figure 1. EBV-miR-BART1 is highly expressed in NPC and associated with clinicopathological features.

Figure 1

(a) MiRNA expression profile microarray screening. Supervised hierarchical cluster analysis of 69 miRNAs that were differentially expressed between 20 NPC and 20 NP biopsies (universal test P<0.005, fold-change >1.5, false discovery rate <0.05). Left: heatmap of the 69 miRNAs differentially expressed between NPC and NP samples. Red represents upregulated miRNAs and blue for downregulated miRNAs. Right-up: the top seven upregulated EBV BART miRNAs clustered together. Right-down: a volcano plot for the visualization of differentially expressed miRNAs with significance cut off P<0.005 and fold-change ≥1.5 symmetrically in NPC compared with NP. The top 11 upregulated EBV BART miRNAs in NPC were highlighted by a red dot-line square. (b) EBV-miR-BART1 was highly expressed in late pathological stages of NPC. The expression of EBV-miR-BART1 in a separated cohort of 82 NPC samples was determined by qRT–PCR. RPU6B was used for normalizing the expression of BART1-5p or BART1-3p. Student's t-test, mean±s.e.m., *P<0.05, **P<0.01. (c) EBV-miR-BART1 was highly expressed in advanced clinical stages of NPC. Both BART1-5p and BART1-3p were highly expressed in advanced clinical stages (III–IV) compared with that of early clinical stages (I–II). Student's t-test, mean±s.e.m., *P<0.05, **P<0.01.